2022
DOI: 10.1016/j.neubiorev.2021.11.032
|View full text |Cite
|
Sign up to set email alerts
|

New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
66
0
1

Year Published

2022
2022
2025
2025

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 52 publications
(71 citation statements)
references
References 143 publications
0
66
0
1
Order By: Relevance
“…Use of pimavanserin in conjunction with subtherapeutic doses of risperidone or haloperidol in psychosis in chronic schizophrenia did not show differences in motor AEs or as measured by SAS or BARS compared to placebo (n = 423) [ 84 ]. Very preliminary evidence (n = 403) for efficacy and similar tolerability in adjunctive treatment of negative symptoms in schizophrenia also exists without increase in DIMD while other studies are ongoing [ 88 89 90 91 ]. No studies have specifically cited or examined the risk of tardive syndromes with pimavanserin.…”
Section: Incidence Of Dimd With Novel Antipsychoticsmentioning
confidence: 99%
See 2 more Smart Citations
“…Use of pimavanserin in conjunction with subtherapeutic doses of risperidone or haloperidol in psychosis in chronic schizophrenia did not show differences in motor AEs or as measured by SAS or BARS compared to placebo (n = 423) [ 84 ]. Very preliminary evidence (n = 403) for efficacy and similar tolerability in adjunctive treatment of negative symptoms in schizophrenia also exists without increase in DIMD while other studies are ongoing [ 88 89 90 91 ]. No studies have specifically cited or examined the risk of tardive syndromes with pimavanserin.…”
Section: Incidence Of Dimd With Novel Antipsychoticsmentioning
confidence: 99%
“…Roluperidone is a high-affinity 5-HT 2A antagonist and σ2R antagonist [ 91 ]. Early trials have shown modest clinical efficacy without increased DIMD which is unsurprising given its lack of D2R antagonism [ 144 ].…”
Section: Agents With Novel Mechanisms Under Investigationmentioning
confidence: 99%
See 1 more Smart Citation
“…Schizophrenia is among the global most disabling health conditions ( Lee et al, 2016 ) and affects about 21 million people worldwide ( Vos et al, 2016 ; Li et al, 2018 ; Jung et al, 2021 ). People with schizophrenia have a life expectancy 15 years shorter than the general population ( Pillinger et al, 2019 ; Lobo et al, 2021 ). Antipsychotic drugs (ADs) and psychological consultation are commonly used to treat schizophrenia.…”
Section: Introductionmentioning
confidence: 99%
“…9,10,[23][24][25]37 Animal research demonstrated that ulotaront does not produce significant D2 receptor occupancy at clinically relevant doses, suggesting that its therapeutic effect is not dependent on this mechanism of action. 10,38 Ralmitaront is another TAAR1 agonist and is also administered orally once daily. 9,11,31,35,36 These 2 drugs differ in that ralmitaront is a TAAR1 partial agonist, whereas ulotaront is a TAAR1 full agonist.…”
Section: Introductionmentioning
confidence: 99%